COVID-19 and isolation: Risks and implications in the scenario of new variants
Braz. j. infect. dis
; 26(5): 102703, 2022. tab
Article
in English
|
LILACS-Express
| LILACS
| ID: biblio-1403892
Responsible library:
BR1.1
ABSTRACT
Abstract With the emergence of new variants of SARS-CoV-2, questions about transmissibility, vaccine efficacy, and impact on mortality are important to support decision-making in public health measures. Modifications related to transmissibility combined with the fact that much of the population has already been partially exposed to infection and/or vaccination, have stimulated recommendations to reduce the isolation period for COVID-19. However, these new guidelines have raised questions about their effectiveness in reducing contamination and minimizing impact in work environments. Therefore, a collaborative task force was developed to review the subject in a non-systematic manner, answering questions about SARS-CoV-2 variants, COVID-19 vaccines, isolation/quarantine periods, testing to end the isolation period, and the use of masks as mitigation procedures. Overall, COVID-19 vaccines are effective in preventing severe illness and death but are less effective in preventing infection in the case of the Omicron variant. Any strategy that is adopted to reduce the isolation period should take into consideration the epidemiological situation of the geographical region, individual clinical characteristics, and mask for source control. The use of tests for isolation withdrawal should be evaluated with caution, due to results depending on various conditions and may not be reliable.
Full text:
Available
Collection:
International databases
Health context:
SDG3 - Target 3.3 End transmission of communicable diseases
Health problem:
COVID-19
Database:
LILACS
Type of study:
Etiology study
/
Practice guideline
/
Prognostic study
/
Risk factors
Language:
English
Journal:
Braz. j. infect. dis
Journal subject:
Communicable Diseases
Year:
2022
Document type:
Article
Affiliation country:
Brazil
Institution/Affiliation country:
Agência Nacional de Vigilância Sanitária (ANVISA)/BR
/
Associação Brasileira de Alergia e Imunologia/BR
/
Associação Brasileira dos Profissionais em Controle de Infecções e Epidemiologia Hospitalar/BR
/
Ministério da Saúde/BR
/
Ministério do Trabalho e Previdência/BR
/
Secretaria de Estado da Saúde de São Paulo/BR
/
Sociedade Brasileira de Cirurgia Oncológica/BR
/
Sociedade Brasileira de Infectologia/BR
/
Medicina Laboratorial+BR
/
Universidade Estadual Paulista (UNESP)/BR